Skeletal muscle satellite cells establish the cellular reserve program logic: quiescence, niche maintenance, and aging-driven senescent conversion.

PAX7+ satellite cells (steel blue) reside between the myofiber sarcolemma and basal lamina, maintained in reversible G0 quiescence by Notch ligands, extracellular matrix cues, and paracrine VEGF from adjacent vasculature (Zone 1). Niche-enforced quiescence preserves reactivation competence across multiple cycles of injury and repair. With aging, progressive engagement of the p16INK4a/Rb axis drives an irreversible transition through perturbed quiescence to geroconversion, a cell-intrinsic senescent state from which reactivation is no longer possible and injury-induced regeneration fails (Zone 2). The quiescence-to-senescence spectrum (right axis) illustrates this progression: young satellite cells occupy the deepquiescence end; aging drives movement toward irreversible senescence, depleting the reserve. Zone 3 encodes the resilience-risk tradeoff: iterative regenerative capacity across the reproductive lifespan, at the cost of sarcopenic reserve exhaustion through senescent conversion in aged muscle. The core molecular logic, p16INK4a/Rb-dependent quiescence maintenance, niche-enforced reversibility, and aging-driven senescent conversion, recurs across reserve tissue programs and is directly applicable to the breast ARLI system.

Hematopoietic stem cells establish the somatic evolutionary horizon principle: cancer risk without pre-malignant conversion in a long-lived maintained reserve.

HSCs (deep violet) are maintained in stable quiescence within the endosteal niche by CXCL12/CXCR4 retention signals from CAR cells and SCF/c-Kit signaling from sinusoidal endothelium (Zone 1). Unlike skeletal muscle satellite cells, aging does not drive HSCs toward senescent conversion, the reserve persists in stable quiescence across decades with no morphological change. Risk accumulates instead through somatic evolution within the maintained progenitor pool: clones bearing driver mutations in DNMT3A, TET2, and ASXL1 expand gradually to clonal dominance without producing overt disease (CHIP; Zone 2). Clonal dominance is invisible at the cellular level; risk is architectural, not cellular. Zone 3 encodes the resilience-risk tradeoff: lifelong hematopoiesis across the entire lifespan, at the cost of hematologic malignancy risk through an extended somatic evolutionary horizon operating within the stably maintained reserve. The principle is directly applicable to incomplete ARLI: a maintained, proliferation-competent tissue unit confers cancer risk through the extended opportunity it provides for somatic evolution, independent of pre-malignant conversion of reserve cells themselves.

The postmenopausal endometrium illustrates passive reserve dormancy and risk through aberrant reactivation.

Basalis progenitor cells clustered in gland bases at the myometrium interface persist in deep quiescence following menopause, maintained without hormonal stimulation in atrophic but architecturally intact tissue for years to decades (Zone 1). The functional competence of this dormant reserve is demonstrated clinically by the rapid restoration of pre-menopausal endometrial thickness following exogenous estrogen administration, as the quiescent reserve retains full reactivation capacity regardless of time elapsed since menopause. Risk arises not from transformation during dormancy but from aberrant reactivation: unopposed estrogen from obesity-associated aromatization or exogenous hormone regimens triggers abnormal proliferation from the maintained reserve, driving endometrial hyperplasia and carcinoma (Zone 2). The quiescence-to-senescence spectrum (right axis) positions endometrial progenitors at the deep-quiescence end with minimal aging-driven movement; the reserve awaits an external hormonal signal rather than generating internal niche dynamics. Zone 3 encodes the resilience-risk tradeoff: retained regenerative capacity years to decades postmenopause, at the cost of carcinoma risk through unopposed estrogen reactivation of the quiescent basalis reserve. Critically, the postmenopausal endometrium quiesces passively; minimal active local niche signal generation is required, and the reserve awaits an external hormonal cue. This is in direct contrast to the breast reserve, which requires active local paracrine maintenance in the absence of systemic hormonal input and is sustained rather than resolved by its immune-stromal microenvironment.

The breast TDLU reserve operates at architectural rather than cellular scale, requiring active local niche maintenance in the absence of systemic hormonal input.

The unit of reserve in incomplete ARLI is an entire functional terminal duct lobular unit: epithelium, intralobular stroma, vasculature, and immune constituents together (dashed boundary), rather than a single stem-cell compartment. This architectural scale implies a requirement not dependent on canonical cell-level reserves: active local paracrine signal generation is needed to sustain the unit after systemic ovarian input has withdrawn. In the maintained state (left), senescent stromal cells are proposed to substitute in part for withdrawn endocrine support through SASP-derived epithelial maintenance signals such as AREG and IL-6, while macrophages and other immune/stromal components contribute to a trophic microenvironment. The aging failure mode (right) is distinct from the comparator systems: rather than reserve depletion through senescent collapse or passive dormancy awaiting reactivation, the breast niche becomes progressively self-sustaining as senescent burden accumulates and immune clearance fails despite continued immune-cell presence. The resilience-risk tradeoff is maintenance of lobular architecture and epithelial capacity across reproductive years at the cost of a chronically survival-permissive microenvironment that extends the somatic evolutionary horizon of the tissue unit.

Schematic summary of evidence that incomplete age-related lobular involution is a biologically active maintained tissue state.

(A) Wide-field cross-section of postmenopausal breast tissue showing two lobular fates within the same adipose field. Complete ARLI (left): a collapsed, hypocellular lobular remnant with quiescent stroma embedded in interlobular fat. Incomplete ARLI (right): an architecturally intact terminal duct lobular unit with organized acinar profiles and a biologically active intralobular stroma containing senescent fibroblasts, quiescent fibroblasts, macrophages, and persistent epithelial structures. Ovarian estrogen withdrawal is indicated above; the lobular niche persists despite it. Anatomical inset indicates field of view within the mammary ductal tree. (B) Two lines of evidence that persistent lobules are embedded in a biologically active microenvironment rather than passively persisting. Left: in histologically normal breast tissue from breast cancer patients, pro-inflammatory markers IL-6, TNF-α, CRP, COX-2, leptin, SAA1, and IL-8, together with IL-10, were inversely associated with complete involution after age adjustment. Right: single-cell transcriptomic and epigenomic profiling of aged murine mammary tissue reveals coordinated remodeling across stromal, immune, and epithelial compartments, with spatial co-localization of aged immune and epithelial cells.

Conceptual model of the menopausal transition as a biological control point for ARLI trajectory.

The x-axis represents years from the final menstrual period, from perimenopause through established postmenopause. Before the transition, tissue fate trajectories are not yet divergent; what matters is immune competence and senescent burden at the control point, not chronological age alone. Two post-transition trajectories are shown: a resolving trajectory (teal), in which senescent cells are cleared, SASP burden declines, and lobular regression completes toward lower risk; and a locking trajectory (amber), in which clearance capacity becomes insufficient, senescent burden rises, and a self-sustaining niche lock is established. Companion traces depict NK cytotoxic activity and senescent burden along each trajectory. The shaded perimenopausal window represents the period of greatest biological plasticity and therefore the period of greatest intervention opportunity. The timing principle has a clinical precedent: responsiveness to menopausal hormone therapy depends on the state of the target tissue at the time therapy is initiated. The same logic is proposed to govern reserve niche interventions.

Comparison of classical view and reserve niche model.

The classical passive target model interprets incomplete age-related lobular involution (ARLI) as residual epithelial tissue available for oncogenic transformation, leaving unexplained why persistence stalls at menopause. The reserve niche model proposes that the menopausal transition is a biological control point at which immune competence determines tissue fate. When immune surveillance is preserved, senescent epithelial cells are cleared and lobular regression completes (Resolution, left). When immune evasion is established, senescent cells persist and sustain residual epithelium through SASP-mediated paracrine signaling, EGFR ligands, and an M2-like macrophage niche (The Niche Lock, right). This reframes risk stratification from residual tissue volume toward microenvironmental senescent burden and immune surveillance competence.

Proposed mechanism-based intervention map for the senescent-immune niche lock.

The x-axis runs from the menopausal control point to established postmenopause. The resolving trajectory (teal) requires monitoring rather than active intervention. The locking trajectory (amber) presents three intervention classes, each mapped to a mechanistic arm of the hypothesis and each expected to show timing-dependent efficacy. Arrow weight encodes predicted timing-dependent efficacy, with earlier intervention expected to be more effective than later intervention once the niche becomes self-sustaining. Senolytic clearance (Arm 3): dasatinib plus quercetin or navitoclax are proposed to reduce established senescent burden and disrupt SASP-dependent niche maintenance; clinical feasibility has been demonstrated for dasatinib plus quercetin in idiopathic pulmonary fibrosis, whereas navitoclax provides primary senolytic precedent in multiple senescent cell models. Immune restoration (Arm 2): NKG2A blockade, anti-CD47/SIRPa approaches, strategies aimed at restoring MerTK-dependent efferocytosis, and NK adoptive transfer are proposed to address the convergent clearance failures of the niche lock. SASP attenuation (Arm 1): senomorphics, EGFR pathway modulation, and IL-6/STAT3 axis targeting are proposed to reduce paracrine survival signals to residual epithelium. Perimenopausal monitoring biomarkers, shown at upper right, represent candidate indicators for identifying women at risk of niche lock formation during the window of greatest intervention opportunity. The footer encodes the central translational principle: menopausal timing relative to the control point is not merely a covariate but a primary stratification variable that is likely to determine intervention efficacy.